Abstract: A direct reductive amination of aldehydes, ketones, and keto acids with trifluoroacetoxyborane-amines (TFAB-amines), which are mild reductive amination agents prepared by monoacetoxylation of borane-amines; Aromatic and aliphatic lactams are obtained via a tandem reductive amination-cycloamidation of keto acids using TFAB-amine.

Abstract: The present invention relates to a process for the preparation of aminoboranes (RR?N—BH2), and aminoborane-amine complexes (RR?N—BH2:NRR?R?), wherein R, and R? of the aminoborane can be the same or different alkyl groups, and R, R?, and R? of the amine complex can be the same or different alkyl groups or hydrogen. The dialkylaminoboranes have been utilized for the preparation of aryl and alkenylboronate esters via dehaloborylation of the corresponding aryl or alkenyl halides, followed by treatment with alcohols or diols. The process and the products thereof are within the scope of this disclosure.

Abstract: The present invention generally relates to a process for selective and direct activation and subsequent amidation of aliphatic and aromatic carboxylic acids to afford an amide R3CONR1R2. That the process is capable of delivering gaseous or low-boiling point amines provides a major advantage over existing methodologies, which involves an intermediate of triacyloxyborane-amine complex [(R3CO2)3—B—NHR1R2]. This procedure readily produces primary, secondary, and tertiary amides, and is compatible with the chirality of the acid and amine involved. The preparation of known pharmaceutical molecules and intermediates has also been demonstrated.

Abstract: The present invention generally relates to compounds, composition matters, and methods for the treatment of a patient with an infection caused by microorganisms, including bacterial, viral, and fungal infections. In particular, this disclosure relates to safe, highly potent and fast acting antimicrobial agents ?-methylene and ?-aminomethyl lactones, lactams, iminolactones, and iminolactams, thiolactones, thionolactones, thiolactams, and thionolactams having a formula of I, II, III, or IV, for the treatment of viral and bacterial infections, especially for infections caused by methicillin-resistant Staphylococcus aureus (MRSA).